Evidence map›Paper›PMID 40890106›Full record

ArticleNature communications2025

Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma.

Jiekun Yang, Cassia Wang, Doris Fu, Li-Lun Ho, Kyriakitsa Galani, Lee Chen, Jose Gonzalez, Jolene Fu, Amy Y Huang, Dennie T Frederick and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Dendritic cell PD-L2 restrains intratumoral CD8bioRxiv : the preprint server for biology · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. TOPK Suppresses the CD8Cancer communications (London, England) · 2026
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Jiekun Yang *Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA. jackie.yang@rutgers.edu.ORCID http://orcid.org/0000-0003-0920-052X
Cassia Wang *Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Doris Fu *Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Li-Lun HoComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Kyriakitsa GalaniComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Lee ChenComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0009-0007-4813-7515
Jose GonzalezDepartment of Genetics, School of Arts and Sciences, Rutgers University-New Brunswick, Piscataway, NJ, USA.
Jolene FuDepartment of Genetics, School of Arts and Sciences, Rutgers University-New Brunswick, Piscataway, NJ, USA.
Amy Y HuangBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-6646-6503
Dennie T FrederickDivision of Medical Oncology, Department of Medicine, Mass General Brigham, Boston, MA, USA.
Liang HeComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Mukta AsnaniDepartment of Genetics, School of Arts and Sciences, Rutgers University-New Brunswick, Piscataway, NJ, USA.
Rahul TackeComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Emily J RobitschekBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Sandeep K YadavDepartment of Genomic Medicine and MDACC Epigenomics Therapy Initiative, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6999-040X
Wentao DengDepartment of Genomic Medicine and MDACC Epigenomics Therapy Initiative, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kelly P BurkeBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-2187-0147
Tatyana SharovaDivision of Gastrointestinal and Oncologic Surgery, Department of Surgery, Mass General Brigham, Boston, MA, USA.
Ryan J SullivanHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5344-6645
Sarah WeissMedical Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA.ORCID http://orcid.org/0000-0002-1106-7089
Kunal RaiDepartment of Genomic Medicine and MDACC Epigenomics Therapy Initiative, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2321-6894
David LiuBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-0346-5033
Genevieve M BolandBroad Institute of MIT and Harvard, Cambridge, MA, USA. GMBOLAND@MGH.HARVARD.EDU.ORCID http://orcid.org/0000-0002-7522-6173
Manolis KellisComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA. manoli@mit.edu.ORCID http://orcid.org/0000-0001-7113-9630

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, yet most patients fail to achieve durable responses. To better understand the tumor microenvironment (TME), we analyze single-cell RNA-seq (~189 K cells) from 36 metastatic melanoma samples, defining 14 cell types, 55 subtypes, and 15 transcriptional hallmarks of malignant cells. Correlations between cell subtype proportions reveal six distinct clusters, with a mature dendritic cell subtype enriched in immunoregulatory molecules (mregDC) linked to naive T and B cells. Importantly, mregDC abundance predicts progression-free survival (PFS) with ICIs and other therapies, especially when combined with the TCF7 + /- CD8 T cell ratio. Analysis of an independent cohort (n = 318) validates mregDC as a predictive biomarker for anti-CTLA-4 plus anti-PD-1 therapies. Further characterization of mregDCs versus conventional dendritic cells (cDC1/cDC2) highlights their unique transcriptional, epigenetic (single-nucleus ATAC-seq data for cDCs from 14 matched samples), and interaction profiles, offering new insights for improving immunotherapy response and guiding future combination treatments.

Indexed as

Dendritic CellsImmune Checkpoint InhibitorsMelanomaProgrammed Cell Death 1 ReceptorCD8-Positive T-LymphocytesCell MovementFemaleHumansMaleTumor MicroenvironmentImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID40890106
PMCPMC12402436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.